Home › Juvenile Myelomonocytic Leukemia › Indiana › Indianapolis
Juvenile Myelomonocytic Leukemia clinical trials in Indianapolis, IN
3 studies for Juvenile Myelomonocytic Leukemia are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RecruitingPhase 1/2
- Indiana University/Riley Hospital for Children, Indianapolis
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
RecruitingPhase 1
- Riley Hospital for Children, Indianapolis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Riley Hospital for Children, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Juvenile Myelomonocytic Leukemia trials in other cities
- Philadelphia, PA4 studies
- Minneapolis, MN4 studies
- Boston, MA3 studies
- Memphis, TN3 studies
- Atlanta, GA3 studies
- San Francisco, CA3 studies
- New York City, NY3 studies
- Chicago, IL3 studies
- Ann Arbor, MI3 studies
- Cincinnati, OH3 studies
- Washington, DC3 studies
- Seattle, WA3 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)24 studies
- Heart Failure23 studies
- Obesity20 studies
- Breast Cancer20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer18 studies
- Ovarian Cancer17 studies
- Cardiovascular Disease17 studies
- Lung Cancer16 studies
- Type 1 Diabetes14 studies
- Endometrial Cancer14 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.